

SENSITIZATION OF HER-2/NEU OVEREXPRESSING

CANCER CELLS TO CHEMOTHERAPY

ABSTRACT

5 The present invention relates to methods for the inhibition, of the gene product
of the *neu* oncogene, p185*neu* tyrosine kinase. Over-expression of the *neu* oncogene
leads to chemoresistance. The methods disclosed involve the novel use of E1A and/or
LT in combination with chemotherapeutic drugs to treat carcinoma. Furthermore, E1A
surprisingly potentiates the antineoplastic effects of the chemotherapeutic agents. The
inventors propose that E1A sensitizes cancer cells such that they become amenable to
10 treatment by chemotherapeutic drugs.